Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Indaptus Therapeutics, Inc. Director's Dealing 2022

Oct 3, 2022

35475_dirs_2022-10-03_979a0860-c43c-4c8b-9bca-3b29f1e01235.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Indaptus Therapeutics, Inc. (INDP)
CIK: 0001857044
Period of Report: 2022-09-30

Reporting Person: Karah Hila (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2022-09-30 Stock Option (right to buy) $2.16 A 13750 Acquired 2032-09-30 Common Stock (13750) Direct

Footnotes

F1: The stock option vests and becomes exercisable on September 30, 2023.